ArticleCurrent treatment options in neurology2011
Acute migraine therapy: new drugs and new approaches.
Article in Current treatment options in neurology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 63 citations in OpenAlex.
- The effects of a multispecies probiotic on migraine and markers of intestinal permeability-results of a randomized placebo-controlled study.European journal of clinical nutrition · 2017Trial
- ephrin-B2 promotes nociceptive plasticity and hyperalgesic priming through EphB2-MNK-eIF4E signaling in both mice and humans.Pharmacological research · 2024Article
- Transcranial Magnetic Stimulation as a Therapy for Migraine: An Overview of Systematic Reviews.Journal of pain research · 2023Article
- Nutrients to Improve Mitochondrial Function to Reduce Brain Energy Deficit and Oxidative Stress in Migraine.Nutrients · 2021Review
- Kynurenine Pathway of Tryptophan Metabolism in Migraine and Functional Gastrointestinal Disorders.International journal of molecular sciences · 2021Review
- Clinical trials on pain lowering effect of ginger: A narrative review.Phytotherapy research : PTR · 2020Review
- Inflammation induces developmentally regulated sumatriptan inhibition of spinal synaptic transmission.British journal of pharmacology · 2020Article
- Lasmiditan mechanism of action - review of a selective 5-HTThe journal of headache and pain · 2020Review
- The need for new acutely acting antimigraine drugs: moving safely outside acute medication overuse.The journal of headache and pain · 2019Review
- Contributions of Nociresponsive Area 3a to Normal and Abnormal Somatosensory Perception.The journal of pain · 2019Review
- Assessment Of Spanlastic Vesicles Of Zolmitriptan For Treating Migraine In Rats.Drug design, development and therapy · 2019Article
- The PPI network analysis of mRNA expression profile of uterus from primary dysmenorrheal rats.Scientific reports · 2018Article
- Combined preconditioning with hypoxia and GYKI-52466 protects rats from cerebral ischemic injury by HIF-1α/eNOS pathway.American journal of translational research · 2017Article
- Targeting CGRP: A New Era for Migraine Treatment.CNS drugs · 2015Review
- Analgesic Effect of Electroacupuncture in a Mouse Fibromyalgia Model: Roles of TRPV1, TRPV4, and pERK.PloS one · 2015Article
- [Pain-relieving effect of CGRP antagonism on inflammatory pain].Schmerz (Berlin, Germany) · 2014Article
- Migraine associated with gastrointestinal disorders: review of the literature and clinical implications.Frontiers in neurology · 2014Review
- Therapeutic effects and safety of olcegepant and telcagepant for migraine: A meta-analysis.Neural regeneration research · 2013Article
- Advances in drug development for acute migraine.Drugs · 2012Article
- Treatment of perimenstrual migraine with triptans: an update.Current pain and headache reports · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
opinion statementThe conceptual shift of our understanding of migraine from a vascular disorder to a brain disorder has dramatically altered the approach to the development of new medicines in the field. Current pharmacologic treatments of acute migraine consist of nonspecific and relatively specific agents. Migraine-specific drugs comprise two classes, the ergot alkaloid derivatives and the triptans, serotonin 5-HT(1B/1D) receptor agonists. The ergots, consisting of ergotamine and dihydroergotamine (DHE), are the oldest specific antimigraine drugs available and are considered relatively safe and effective. Ergotamine has been used less extensively because of its adverse effects; DHE is better tolerated. The triptan era, beginning in the 1990s, was a period of considerable change, although these medicines retained vasoconstrictor actions. New methods of delivering older drugs include orally inhaled DHE and the transdermal formulation of sumatriptan, both currently under study. Novel medicines being developed are targeted at neural sites of action. Serotonin 5-HT(1F) receptor agonists have proven effective in phase II studies and have no vascular actions. Calcitonin gene-related peptide (CGRP) receptor antagonists are another promising nonvasoconstrictor approach to treating acute migraine. Olcegepant (BIBN4096BS) and telcagepant (MK-0974) have been shown to be safe and effective in phase I, II, and (for telcagepant) phase III clinical trials. Other targets under investigation include glutamate (AMPA/kainate), TRPV1, prostanoid EP4, and nitric oxide synthase. With new neural targets and the potential for therapeutic advances, the next era of antimigraine medications is near.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.